Impact News +++ Ultragenyx erhält FDA-Zulassung für Gentherapie gegen seltene Krankheit (Investing.com DE) +++ ULTRAGENYX Aktie +4,04%

REGENERON Aktie

>REGENERON Aktienkurs

677.7 EUR +0.4% (TradegateBSX)

Ask: 690.1 EUR / 14 Stück

Bid: 685.1 EUR / 14 Stück

Tagesumsatz: 42 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: -2,1%

1 Monat: -2,9%

3 Monate: +28,4%

6 Monate: +2,7%

1 Jahr: +37,0%

laufendes Jahr: +2,2%

>REGENERON Aktie

Profil:

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and met..
>Volltext..

Insiderhandel:

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>REGENERON Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen, Stoffwechselerkrankungen (Diabetes/ Adipositas), Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

17.09.26 - 16:36	Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth \| DelveInsight (PR Newswire)
	The expected launch of potential therapies such as Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others......

16.09.26 - 13:06	Regeneron Pharmaceuticals Aktie: HSBC sieht neues Potenzial - Pipeline und Bewertung treiben Kursziel (Aktiencheck)
	London (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von HSBC: Rajesh Kumar, Analyst von HSBC, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) weiterhin mit "buy" ein und hebt das Kursziel von 800 auf 920 USD an. [mehr]...

15.09.26 - 15:12	Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
	Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now....

14.09.26 - 20:06	Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

14.09.26 - 18:48	REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today′s September 14, 2026 Lead Plaintiff Deadline in Securities Class Action (PR Newswire)
	SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

13.09.26 - 15:30	REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces (PR Newswire)
	SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September......

10.09.26 - 18:00	REGN 4-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
	SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

10.09.26 - 16:48	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
	NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......

10.09.26 - 16:15	SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN (PR Newswire)
	Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis. NEW YORK, Sept. 10,......

10.09.26 - 13:57	Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Regeneron to Contact Him Directly to Discuss Their Options NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds......

10.09.26 - 02:18	REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit (PR Newswire)
	SAN DIEGO, Sept. 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14,......

09.09.26 - 23:03	REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
	SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

09.09.26 - 16:48	Regeneron auf Wells-Fargo-Konferenz: Wachstum auf breiterer Basis (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.09.26 - 16:15	Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN (PR Newswire)
	Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations. NEW......

09.09.26 - 13:06	Recent Stanton graduate wins Humane Science Award from National Anti-Vivisection Society (PR Newswire)
	Alan Alwakeel among five young scientists worldwide to earn a $3,000 prize at 2026 Regeneron International Science and Engineering Fair JACKSONVILLE, Fla., Sept. 9, 2026 /PRNewswire/ -- Alan Alwakeel, a recent graduate of Stanton College Preparatory School in Jacksonville, Florida, was......

07.09.26 - 19:21	REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
	SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......

04.09.26 - 21:00	Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? (Fool)
	They could both outperform the market over the medium term, but one appears to have a clear edge....

04.09.26 - 03:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 340000 USD (Insiderkauf)
	Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-09-02...

04.09.26 - 03:01	Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 969708 USD (Insiderkauf)
	Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-03...

04.09.26 - 03:01	Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 1032750 USD (Insiderkauf)
	Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-02...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Fälle weder den ganzen Wald, noch komm ohne Holz nach Hause. - Sprichwort Serbien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram